These are terms you may come across when reading about or discussing advanced ovarian cancer, treatment with LYNPARZA, and BRCA testing.


Advocacy group

An organization created to help patients deal with a disease or condition. It usually supplies information about disease, treatment, and support and often provides stories from patients with the same disease or condition who share their experiences.


A condition in which you do not have enough healthy red blood cells to carry adequate oxygen to your tissues. Chemotherapy often results in a temporary disruption in the body’s ability to produce red blood cells. Red blood cells deliver oxygen to muscles and organs, and a lack of oxygen explains why chemotherapy can leave people feeling tired, weak, or emotionally or mentally exhausted.


Human genes in DNA that normally shut down cancer cells before they can harm the body. These BReast CAncer (BRCA1/BRCA2) genes can contain mutations that interfere with their ability to suppress tumors, increasing the risk of developing ovarian or breast cancer.

BRCA1 and BRCA2 tests

Genetic tests that check blood or saliva for BRCA1 and BRCA2 mutations. Results may inform treatment decisions physicians make for women diagnosed with ovarian cancer.


A term for disease in which abnormal cells divide without control and can invade nearby tissues.


Medicines that are formulated to kill cancer cells. Chemotherapeutic agents attack cells that replicate quickly.

Clinical trial

A well-monitored study of medicine (or “investigational therapy”) to determine how well a drug works and how safe it is in humans before it is made available to the general public. Independent committees make sure that any risks in the study are small and are worth the potential benefits. Participating in a clinical trial is one way patients can take advantage of the possible positive outcomes of the medicine.


The center of every cell in the body contains material with the abbreviated name DNA, which determine our body’s chemical makeup. In humans, genes are located on 23 pairs of DNA strands called chromosomes. Normally, when DNA is damaged, the cell repairs the damage or it dies.

FDA approved

Permission from the Food and Drug Administration to make a specific drug or product available to the general public.

Genetic mutation

A permanent change in the DNA sequence that makes up a gene. It can be inherited (passed down from a parent) or acquired (a result of environmental factors, such as ultraviolet radiation from the sun).


The middle number in a sorted list of numbers.


A change in hereditary material (DNA) involving either a physical or a biochemical change in the makeup of genes.


The generic name (not a brand name) for LYNPARZA.


One of the body’s natural families of proteins that helps repair a cell’s DNA when it becomes damaged.

PARP Inhibitor

A medicine that blocks the PARP enzyme from performing its natural function. LYNPARZA is a PARP inhibitor.


A set of numbers defined by its upper and lower limits.


Outcome after treatment, such as the reaction to a medicine or any other therapy.


An abnormal mass of tissue that may be cancerous (malignant), precancerous (premalignant), or benign (not cancerous).


For over 2 years, doctors have been using LYNPARZA to treat patients with BRCA-mutated advanced ovarian cancer who have received 3 or more prior lines of chemotherapy

Learn more

BRCA Testing

Testing for a BRCA1/BRCA2 mutation will help determine who may be eligible for treatment with LYNPARZA

Get the facts


LYNPARZA is a prescription medicine used to treat women with advanced ovarian cancer who have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and have a certain type of abnormal inherited BRCA gene.

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Please see Important Safety Information below.


There are no contraindications (a condition in which the treatment should not be used) for LYNPARZA.

LYNPARZA may cause serious side effects that can lead to death including bone marrow problems and lung problems. Some people who have..Read More ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed bone marrow problems called Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) during treatment with LYNPARZA. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms to discuss with your healthcare provider include weakness, weight loss, fever, frequent infections, blood in your urine/stool, shortness of breath, feeling very tired, and bruising or bleeding more easily.

You will undergo blood tests before, and every month during, treatment with LYNPARZA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve.

Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis (inflammation of the lungs).

Before you take LYNPARZA, tell your healthcare provider about all of your medical conditions including:

  • lung or breathing problems
  • liver problems
  • kidney problems
  • are pregnant or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage).
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after receiving the last dose of LYNPARZA.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby.

Avoid grapefruit, grapefruit juice and Seville oranges during treatment as they may increase the levels of LYNPARZA in your blood.

The most common side effects are anemia, nausea or vomiting, tiredness or weakness, diarrhea, indigestion or heartburn, headache, loss of appetite, changes in how food tastes, changes in kidney function blood tests, sore throat or runny nose, upper respiratory infection, cough, pain in the joints, muscles, and back, rash, and pain or discomfort in the stomach area.

These are not all the possible side effects of LYNPARZA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088 1-800-FDA-1088.

Please see complete Prescribing Information, including Patient Information (Medication Guide).

The information on this Web site should not take the place of talking with your doctor or healthcare professional. If you have any questions about your condition, or if you would like more information about LYNPARZA, talk to your doctor or pharmacist. Only you and your healthcare professional can decide if LYNPARZA is right for you.